<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The CD56 antigen is normally expressed on natural-killer cells but has additionally been shown to be present on a variety of <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e>, including a subset of <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>There is disagreement, however, about its prognostic significance and its association with specific cytogenetic abnormalities </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> clinical samples from June 1994, through September 1995, with increased myeloblasts were analyzed by multiparameter flow cytometry for anomalous expression of CD56 </plain></SENT>
<SENT sid="3" pm="."><plain>Patients with CD56+ blast cells were selected, and morphologic review was performed </plain></SENT>
<SENT sid="4" pm="."><plain>Clinical information was obtained, and cytogenetic data were reviewed </plain></SENT>
<SENT sid="5" pm="."><plain>Southern blot analysis to detect rearrangement of the mixed lineage <z:hpo ids='HP_0001909'>leukemia</z:hpo> (MLL) gene was performed when possible </plain></SENT>
<SENT sid="6" pm="."><plain>The samples from 23 of 114 patients studied demonstrated anomalous expression of CD56 on myeloblasts, including patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), and <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> in <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast crisis</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>The samples from 10 of 15 patients with CD56+ <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> demonstrated at least partial monocytic differentiation </plain></SENT>
<SENT sid="8" pm="."><plain>Dysplastic features were displayed in the samples of 12 patients </plain></SENT>
<SENT sid="9" pm="."><plain>Correlation with specific cytogenetic abnormalities was not found </plain></SENT>
<SENT sid="10" pm="."><plain>The MLL gene was rearranged in five of 18 patients </plain></SENT>
<SENT sid="11" pm="."><plain>Seventeen patients have died, with a median survival of 4.6 months for patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>Three have sustained a complete remission </plain></SENT>
<SENT sid="13" pm="."><plain>One has findings of high-grade <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> </plain></SENT>
<SENT sid="14" pm="."><plain>Two were unavailable for follow-up </plain></SENT>
<SENT sid="15" pm="."><plain>Expression of CD56 was found in 20% of patients with increased myeloblasts, including patients with high-grade <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> in <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast crisis</z:e>, and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="16" pm="."><plain>This phenotype was associated with <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, monocytic differentiation, and rearrangement of the MLL gene </plain></SENT>
</text></document>